AstraZeneca said European regulators had offered a positive opinion for the oral use of its treatment for type-one diabetes.
The Committee for Medicinal Products for Human Use of the European Medicines Agency had also recommended a new indication for the marketing authorisation of the treatment, Forxiga. Forxiga was the first oral medicine to receive a positive recommendation from the EMA for use in type-one diabetes as an adjunct to insulin, when insulin alone did not provide adequate glycaemic control.
'People with type-one diabetes have not seen oral treatment innovation in decades and we believe today's announcement signals an important advancement for them, as well as a broader understanding of the well-established clinical profile of Forxiga for people living with metabolic diseases,' head of cardiovascular, renal and metabolism Elisabeth Bjork said.
At 1:59pm: (LON:AZN) AstraZeneca PLC share price was +33.5p at 5565.5p